| Sep 24 |
EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS; Increasing Valuation to $33 per Share…
|
| Sep 16 |
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
|
| Sep 15 |
ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now
|
| Sep 13 |
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
|
| Sep 11 |
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
|
| Aug 8 |
EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024…
|
| Aug 5 |
ESSA Pharma GAAP EPS of -$0.16 beats by $0.09
|
| Aug 5 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
|
| Jul 1 |
With 40% stake, ESSA Pharma Inc. (NASDAQ:EPIX) seems to have captured hedge funds investors' interest
|
| May 30 |
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
|
